-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Pivotal Phase 3 data in newly diagnosed AML: Exploring the efficacy, safety, and patient management of evolving AML treatment paradigms

Sponsor: Genentech
Program: Product Theaters
Sunday, December 11, 2022: 8:00 AM-9:00 AM
Hall J - Theater 6 (Ernest N. Morial Convention Center)
Melissa Montez, PharmD, Genentech
No relevant conflicts of interest to declare.
This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

See more of: Product Theaters